Clinical Trial Update: TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma [Phase 3]

View source ↗

Summary

Phase 3 trial TJ202 evaluating lenalidomide plus dexamethasone versus lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: TJ Biopharma Co., Ltd. | Conditions: Multiple Myeloma in Relapse, Refractory Multiple Myeloma | Phase 3 | Status: COMPLETED